HilleVax Taps Sean McLoughlin as Chief Operating Officer
By Ben Glickman
HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief.
The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition.
McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company.
McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 07:34 ET (12:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks